Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER vs ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium lactate is a source of bicarbonate precursor. It is metabolized to bicarbonate in the liver, which buffers metabolic acidosis, restoring acid-base balance.
Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.
Alternative to sodium bicarbonate for metabolic acidosis when lactate metabolism is intact,Fluid and electrolyte replenishment,Mild to moderate metabolic acidosis
Fluid and electrolyte replacement,Maintenance of hydration and electrolyte balance in patients unable to tolerate oral intake,Correction of hypovolemia,Mild to moderate metabolic acidosis
Intravenous infusion: The typical adult dose is 300-500 m L of 1/6 Molar sodium lactate solution (approximately 167 m Eq/L each of sodium and lactate, 1 L contains 167 m Eq of sodium and lactate) administered as a continuous intravenous infusion at a rate of 0.5-2.5 m L/kg/hour, adjusted based on the severity of acidosis and clinical response. Maximum infusion rate: 2.5 m L/kg/hour.
Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.
30–60 minutes for lactate conversion; bicarbonate component determined by CO2 excretion.
Not applicable as a fixed drug. Electrolytes have no defined half-life; dextrose is rapidly cleared with a metabolic half-life of approximately 5-10 minutes due to insulin-mediated uptake.
Primarily hepatic gluconeogenesis; lactate is converted to glucose via the Cori cycle, or oxidized to carbon dioxide and water; metabolism requires adequate liver function.
Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, primarily in the liver; insulin promotes cellular uptake. Electrolytes are not metabolized but are excreted or reabsorbed by the kidneys.
Primarily renal as bicarbonate and lactate; <5% unchanged.
Electrolytes and dextrose are primarily excreted renally. Potassium, sodium, chloride, and magnesium are eliminated via kidneys. Dextrose is metabolized to CO2 and water, with negligible renal excretion. Biliary/fecal elimination is minimal (<5%).
Negligible (<1%); does not bind significantly to plasma proteins.
Negligible for electrolytes and dextrose (<5%).
0.4-0.6 L/kg; distributes primarily in extracellular fluid.
Not applicable as a single compound. Electrolytes distribute primarily in extracellular fluid (0.2 L/kg for sodium), total body water (0.6 L/kg for water). Dextrose distributes in total body water (0.55 L/kg).
Intravenous: 100%
Intravenous: 100%.
Contraindicated in severe renal dysfunction (e GFR < 30 m L/min/1.73 m²) due to risk of hypernatremia and volume overload. In patients with e GFR 30-59 m L/min/1.73 m², use with caution, reduce infusion rate by 25-50%, and monitor serum sodium and fluid balance closely.
No specific dose adjustment required; monitor serum electrolytes and fluid status in renal impairment due to risk of hyperkalemia, hypernatremia, or fluid overload.
Contraindicated in severe hepatic impairment (Child-Pugh Class C) due to impaired lactate metabolism. In Child-Pugh Class A or B, use with caution, reduce infusion rate by 50%, and monitor arterial blood gases and lactate levels frequently.
No specific dose adjustment; use with caution in severe hepatic impairment due to potential for fluid and electrolyte disturbances.
Intravenous infusion: Administer 3-5 m L/kg of 1/6 Molar sodium lactate as a bolus over 30 minutes, followed by a continuous infusion at 0.5-1 m L/kg/hour, titrated to correct metabolic acidosis. Maximum infusion rate: 2 m L/kg/hour.
Weight-based: 2-6 m L/kg/hour or as per Holliday-Segar method for maintenance; monitor serum electrolytes closely.
Use with caution due to decreased renal function and higher risk of fluid overload. Start at lower end of dosing range (0.5-1 m L/kg/hour) and monitor serum electrolytes, fluid balance, and renal function closely. Contraindicated if e GFR < 30 m L/min/1.73 m².
Use with caution; consider lower initial rates due to reduced renal function and increased risk of fluid overload; monitor electrolytes and volume status.
None.
None for this product; however, caution is required in patients with congestive heart failure, renal impairment, or conditions predisposing to electrolyte imbalances.
Use with caution in patients with impaired liver function, lactic acidosis, or conditions predisposing to lactic acidosis (e.g., shock, hypoxia). Monitor serum electrolytes and acid-base status. Risk of hyperlactatemia if metabolism is impaired.
Risk of fluid overload in patients with compromised cardiac or renal function,Risk of electrolyte imbalances (hyperkalemia, hyponatremia, hypernatremia),Administration may cause phlebitis or thrombosis,Monitor serum electrolytes, glucose, and fluid balance,Use with caution in patients with diabetes or glucose intolerance,Not for use when hyperosmolality is present
Severe lactic acidosis, hyperlactatemia, severe hepatic impairment, metabolic alkalosis, hypocalcemia, and patients with known hypersensitivity to sodium lactate.
Hyperkalemia,Severe renal impairment (oliguria or anuria),Severe metabolic alkalosis,Hypersensitivity to any component,Patients with known glucose-6-phosphate dehydrogenase deficiency (relative, due to potential for Heinz body formation)
No specific food interactions known. However, patients on sodium-restricted diets should account for the sodium content of this solution (approximately 167 m Eq/L).
No known food interactions. However, monitor dietary intake of sodium, potassium, and chloride to avoid electrolyte imbalances.
Sodium lactate is a normal metabolic intermediate and component of IV fluids. No teratogenic effects are known at therapeutic doses. Risk cannot be ruled out in first trimester, but no specific fetal risks are associated with maternal administration of this physiologic compound.
Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological constituents. However, maternal hyperglycemia from dextrose may increase fetal risks including macrosomia and congenital anomalies if glucose not controlled. First trimester: no direct teratogenicity, but dextrose-induced hyperglycemia may be associated with neural tube defects. Second/third trimester: risk of fetal hyperinsulinemia, macrosomia, neonatal hypoglycemia if maternal glucose elevated.
Sodium lactate is a normal constituent of breast milk. Exogenous administration is unlikely to significantly alter milk levels. M/P ratio not established. Considered compatible with breastfeeding.
Components are normal constituents of human milk. No specific M/P ratio data; dextrose, sodium, potassium, magnesium, chloride, acetate, gluconate are expected to transfer minimally. Use is compatible with breastfeeding. Monitor infant for electrolyte balance only if maternal levels are abnormal.
No dose adjustment required. Physiologic increases in plasma volume during pregnancy may dilute infused fluids, but standard dosing based on clinical status is appropriate.
Pregnancy increases plasma volume and glomerular filtration rate; may require higher infusion rates to achieve desired electrolyte balance. Dextrose load may need adjustment to avoid maternal hyperglycemia, especially in gestational diabetes. No dose changes for electrolyte components themselves; monitor clinical response and serum levels.
Sodium lactate 1/6 Molar is a crystalloid solution providing approximately 167 m Eq/L of sodium and 167 m Eq/L of lactate. It is metabolized to bicarbonate in the liver, making it useful for correcting metabolic acidosis, especially in patients with lactic acidosis or those unable to tolerate bicarbonate due to hypocalcemia or hypercapnia. Monitor serum electrolytes, lactate levels, and acid-base status. Avoid in severe liver dysfunction as conversion to bicarbonate is impaired. Use with caution in patients with heart failure or renal impairment due to sodium load. For intravenous use only; do not administer with calcium-containing solutions due to precipitation risk.
ISOLYTE H IN DEXTROSE 5% is a hypertonic solution (approximately 554 m Osm/L) that provides free water, electrolytes, and calories. Use caution in patients with renal impairment or those at risk for fluid overload. Monitor serum sodium, potassium, chloride, and glucose levels during infusion. Do not administer if solution is discolored or contains particulate matter. Compatible with most IV lines but avoid adding other drugs without checking compatibility.
This medication is a solution that helps correct acid buildup in your blood.,It will be given through a vein (intravenously) by a healthcare professional.,You may need frequent blood tests to monitor your electrolyte levels and acid-base balance.,Inform your doctor if you have liver disease, heart failure, or kidney problems.,Report any signs of fluid overload such as shortness of breath, swelling in the ankles or legs.,Do not take any other medications or supplements without consulting your doctor.,This solution contains sodium; discuss any dietary sodium restrictions with your healthcare provider.
This solution is given through a vein to provide fluids, electrolytes, and sugar.,Tell your healthcare provider if you have kidney problems, heart issues, or if you are on a low-sodium or low-potassium diet.,Report any signs of fluid overload such as swelling, shortness of breath, or rapid weight gain.,You may need blood tests to check your body's electrolyte levels and blood sugar.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER vs ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER is a Electrolyte Solution that works by Sodium lactate is a source of bicarbonate precursor. It is metabolized to bicarbonate in the liver, which buffers metabolic acidosis, restoring acid-base balance.. ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER and ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER is: Intravenous infusion: The typical adult dose is 300-500 m L of 1/6 Molar sodium lactate solution (approximately 167 m Eq/L each of sodium and lactate, 1 L contains 167 m Eq of sodium and lactate) administered as a continuous intravenous infusion at a rate of 0.5-2.5 m L/kg/hour, adjusted based on the severity of acidosis and clinical response. Maximum infusion rate: 2.5 m L/kg/hour.. The standard adult dose of ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER and ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER is classified as Category C. Sodium lactate is a normal metabolic intermediate and component of IV fluids. No teratogenic effects are known at therapeutic doses. Risk cannot be ruled out in first trimester, bu. ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological const. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.